Back to News
research

New Strong Sell Stocks for March 6th

Zacks
Loading...
3 min read
0 likes
⚡ Quantum Brief
Three stocks—Artelo Biosciences (ARTL), Kennedy-Wilson Holdings (KW), and Kimbell Royalty Partners (KRP)—were added to the Zacks Rank #5 "Strong Sell" list on March 6, 2025, due to sharp earnings estimate declines. Artelo Biosciences, a clinical-stage biopharma firm, saw its 2025 earnings forecast slashed by 50.5% over the past 60 days, signaling deepening financial or operational struggles. Kennedy-Wilson Holdings, a real estate investment company, faced the steepest revision—a 115.1% downward adjustment—highlighting severe sector or company-specific headwinds in early 2025. Kimbell Royalty Partners, an oil and gas royalty firm, experienced an 18.3% earnings estimate cut, reflecting volatility in energy markets or asset performance. The rankings stem from Zacks’ earnings revision model, which flags stocks with deteriorating analyst outlooks, often preceding further price declines.
AI Audio Summary
0:00 / 0:00
Click to play
Untitled design (36).png
Quantum News · Media Library

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks New Strong Sell Stocks for March 6th March 06, 2025 — 04:07 am EST Written by Zacks Equity Research for Zacks-> Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Artelo Biosciences, Inc. ARTL is a clinical stage biopharmaceutical company.

The Zacks Consensus Estimate for its current year earnings has been revised 50.5% downward over the last 60 days.Kennedy-Wilson Holdings, Inc. KW is a real estate investment company.

The Zacks Consensus Estimate for its current year earnings has been revised 115.1% downward over the last 60 days.Kimbell Royalty Partners, LP KRP is an oil and gas mineral and royalty company.

The Zacks Consensus Estimate for its current year earnings has been revised 18.3% downward over the last 60 days.View the entire Zacks Rank #5 List. Only $1 to See All Zacks' Buys and Sells We're not kidding. Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportKennedy-Wilson Holdings Inc. (KW) : Free Stock Analysis ReportKimbell Royalty (KRP) : Free Stock Analysis ReportArtelo Biosciences, Inc. (ARTL) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags StocksInvestingHow to Invest Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned KW KRP ARTL More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Read Original

Tags

drug-discovery

Source Information

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.